Our Company


President and Chief Executive Officer

Warren C. Lau is Nexus BioPharma Inc.'s President and Chief Executive Officer and Director, a position he has held since the formation of the company. Previously, Mr. Lau was a biotech entrepreneur and product development visionary many times over.

He also served as Founder, President and CEO, and Chief Financial Officer of MetaStat, Inc. (MTST-OTCBB) for six years.

In 2003, Mr. Lau founded PharmaFrontiers Corp. (now Opexa Therapeutics, Inc OPXA-NASDAQ). He also served as President, Chief Executive Officer, Treasurer and Board Member. Opexa has subsequently negotiated product development deals with Novartis AG and Merck Serono.

In 1996, Mr. Lau started Adventrx Pharmaceuticals, Inc., now Mast Therapeutics, Inc. (MSTX-NYSE MKT). He served as President and CEO and as a member of its Board of Directors from July 1996 through November 2001. During his time as President and CEO, the Company completed two acquisitions - with Immune Complex Corporation (1997) and Biokeys Pharmaceuticals, Inc.

From November 1997 to September 1998, Mr. Lau served as a director of Immune Complex Corporation and Synthetic Genetics, Inc., privately held biotechnology companies.

Dr Pessin

PhD, Chair of Scientific & Clinical Advisory Board

Dr. Pessin is the Judy R. & Alfred A. Rosenberg Professorial Chair in Diabetes Research and Director of the Diabetes Research Center, Department of Medicine at the Albert Einstein College of Medicine.

​He also serves as Professor in the Departments of Medicine (Endocrinology) and Molecular Pharmacology.​

Dr. Pessin directs the Einstein-Mount Sinai Diabetes Research Center, one of only sixteen NIH-funded diabetes centers of its kind in the country.

​He guides the research of more than 90 scientists investigating type 1 (formerly juvenile) and type 2 (formerly adult-onset) diabetes. 

Dr. Pessin is associate editor of Diabetes, the peer-reviewed journal of the American Diabetes Association, and the former editor-in-chief of Endocrinology and the American Journal of Physiology - Endocrinology and Metabolism. He has received the Eli Lilly Outstanding Investigator Award of the American Diabetes Association and the Mary Jane Kugel Award of the Juvenile Diabetes Research Foundation International.

Dr einhorn

MD, Scientific & Clinical Advisory Board

Dan Einhorn, M.D. is medical director of the Scripps Whittier Diabetes Institute, clinical professor of medicine (voluntary) at UC San Diego, president of Diabetes and Endocrine Associates, and associate editor of the Journal of Diabetes.

Dr. Einhorn’s experience includes acting as a trustee and past-president of the American College of Endocrinology (ACE), a founding member and current regent of the ACE Foundation, and past-president of the American Association of Clinical Endocrinologists (AACE).

Dr. Einhorn received his BA at Yale (Summa cum Laude), his MD at Tufts (AOA) and his post-graduate training at Harvard.

He has been in leadership at AACE and ACE for over 20 years during which time he has participated in writing many national guidelines, including those for diabetes, pre-diabetes, inpatient diabetes management, and obesity.

Dr. Einhorn has been on the teaching faculty of every AACE/ACE annual meeting since 1994, chairing the meeting in 2009, and he continues to be a practicing physician.

He has devoted his practice exclusively to the care of adults with endocrine disorders, including diabetes, thyroid disease, osteoporosis, lipid disorders, polycystic ovarian syndrome, adrenal disease, parathyroid disease and diagnostic dilemmas that may have a hormonal origin.